|
Name |
Zelkovamycin D
|
Molecular Formula | C36H45N9O10S | |
IUPAC Name* |
(4S,7S,13R,16Z,22R)-7-acetyl-13-ethyl-16-(2-hydroxyethylidene)-4-[(4-methoxy-1H-indol-3-yl)methyl]-7,18,22-trimethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
SMILES |
CC[C@@H]1C(=O)N/C(=C\CO)/C(=O)N(CC(=O)N[C@@H](C2=NC(=CS2)C(=O)N[C@H](C(=O)N[C@@](C(=O)NCC(=O)N1)(C)C(=O)C)CC3=CNC4=C3C(=CC=C4)OC)C)C
|
|
InChI |
InChI=1S/C36H45N9O10S/c1-7-21-30(50)41-23(11-12-46)34(53)45(5)16-28(49)39-18(2)33-43-25(17-56-33)31(51)42-24(13-20-14-37-22-9-8-10-26(55-6)29(20)22)32(52)44-36(4,19(3)47)35(54)38-15-27(48)40-21/h8-11,14,17-18,21,24,37,46H,7,12-13,15-16H2,1-6H3,(H,38,54)(H,39,49)(H,40,48)(H,41,50)(H,42,51)(H,44,52)/b23-11-/t18-,21-,24+,36+/m1/s1
|
|
InChIKey |
IDQDOHKLXZSZIG-VQJCRCMASA-N
|
|
Synonyms |
Zelkovamycin D
|
|
CAS | NA | |
PubChem CID | 156582958 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 795.9 | ALogp: | -0.4 |
HBD: | 8 | HBA: | 12 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 298.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 56 | QED Weighted: | 0.117 |
Caco-2 Permeability: | -5.854 | MDCK Permeability: | 0.00000284 |
Pgp-inhibitor: | 0.154 | Pgp-substrate: | 1 |
Human Intestinal Absorption (HIA): | 0.758 | 20% Bioavailability (F20%): | 0.998 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.184 | Plasma Protein Binding (PPB): | 49.03% |
Volume Distribution (VD): | 0.266 | Fu: | 66.50% |
CYP1A2-inhibitor: | 0 | CYP1A2-substrate: | 0.07 |
CYP2C19-inhibitor: | 0.068 | CYP2C19-substrate: | 0.035 |
CYP2C9-inhibitor: | 0.14 | CYP2C9-substrate: | 0.086 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.068 |
CYP3A4-inhibitor: | 0.082 | CYP3A4-substrate: | 0.041 |
Clearance (CL): | 2.056 | Half-life (T1/2): | 0.693 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.198 |
Drug-inuced Liver Injury (DILI): | 0.476 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.007 | Maximum Recommended Daily Dose: | 0.464 |
Skin Sensitization: | 0.278 | Carcinogencity: | 0.01 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.003 |
Respiratory Toxicity: | 0.138 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004434 | 0.840 | D09ZIO | 0.305 | ||||
ENC002016 | 0.825 | D0X9PF | 0.262 | ||||
ENC004432 | 0.815 | D0M2YE | 0.243 | ||||
ENC004433 | 0.739 | D02XIY | 0.239 | ||||
ENC005139 | 0.342 | D07DSQ | 0.239 | ||||
ENC005343 | 0.319 | D0E2OU | 0.226 | ||||
ENC005276 | 0.301 | D00TLP | 0.221 | ||||
ENC005563 | 0.296 | D0Q8NJ | 0.221 | ||||
ENC002515 | 0.293 | D05HPI | 0.220 | ||||
ENC002514 | 0.285 | D0D8XY | 0.219 |